Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition

HIV remains a significant burden, despite expanding HIV prevention tools. Long-acting injectable cabotegravir (CAB-LA) is a new preexposure prophylaxis (PrEP) product. We reviewed existing evidence to determine the efficacy and safety of CAB-LA as PrEP to inform global guidelines. DESIGN: Systematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fonner, Virginia A., Ridgeway, Kathleen, van der Straten, Ariane, Lorenzetti, Lara, Dinh, Nhi, Rodolph, Michelle, Schaefer, Robin, Schmidt, Heather-Marie A., Nguyen, Van Thi Thuy, Radebe, Mopo, Peralta, Hortencia, Baggaley, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Epidemiology and Social
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090368/
https://www.ncbi.nlm.nih.gov/pubmed/36723489
http://dx.doi.org/10.1097/QAD.0000000000003494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090368/
https://www.ncbi.nlm.nih.gov/pubmed/36723489
http://dx.doi.org/10.1097/QAD.0000000000003494

Ejemplares similares